Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:BLU NYSEAMERICAN:CVM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUBELLUS HealthC$0.00C$8.58▼C$19.90C$2.47B-0.2859,471 shs28,666 shsCVMCel-Sci$1.18-0.8%$1.26$0.89▼$13.48$20.62M0.64390,882 shs144,919 shsThe Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUBELLUS Health0.00%0.00%0.00%0.00%0.00%CVMCel-Sci0.00%+0.85%+21.10%-63.13%-81.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUBELLUS HealthC$0.00C$8.58▼C$19.90C$2.47B-0.2859,471 shs28,666 shsCVMCel-Sci$1.18-0.8%$1.26$0.89▼$13.48$20.62M0.64390,882 shs144,919 shsThe Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUBELLUS Health0.00%0.00%0.00%0.00%0.00%CVMCel-Sci0.00%+0.85%+21.10%-63.13%-81.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLUBELLUS Health 0.00N/AN/AN/ACVMCel-Sci 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLUBELLUS HealthC$16K0.00N/A4.67C$2.91 per share0.00CVMCel-SciN/AN/AN/AN/A$2.32 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLUBELLUS Health-C$86.79M-C$0.96N/AN/AN/AN/A-26.76%-16.70%N/ACVMCel-Sci-$25.41M-$9.77N/AN/AN/AN/A-274.86%-126.47%N/ALatest BLU, CVM, and OXB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q2 2026CVMCel-SciN/A-$0.67N/A-$0.67N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBLUBELLUS HealthN/AN/AN/AN/AN/ACVMCel-SciN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLUBELLUS Health0.3233.4216.40CVMCel-Sci0.640.600.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLUBELLUS Health90.41%CVMCel-Sci12.08%Insider OwnershipCompanyInsider OwnershipBLUBELLUS Health10.26%CVMCel-Sci9.93%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLUBELLUS Health74126.81 millionN/ANot OptionableCVMCel-Sci4317.48 million15.74 millionOptionableBLU, CVM, and OXB HeadlinesRecent News About These CompaniesCEL-SCI Corporate Event Calendar | AMEX:CVMJuly 16, 2026 | benzinga.comCEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck CancerJuly 13, 2026 | finance.yahoo.comCEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer CareJune 24, 2026 | businesswire.comCEL-SCI Announces Closing of OfferingJune 16, 2026 | businesswire.comCEL-SCI slides after pricing $2.5M best-efforts common stock offering at $1.00/shareJune 15, 2026 | msn.comCVM Stock Sinks In Pre-Market Trading After Announcing Second Equity Raise For Its Cancer Drug In Just Over A MonthJune 15, 2026 | finance.yahoo.comCEL-SCI Corporation Announces Pricing of OfferingJune 14, 2026 | businesswire.comCEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi ArabiaJune 12, 2026 | tmcnet.comCEL-SCI Reports Fiscal Second Quarter 2026 ResultsMay 18, 2026 | finance.yahoo.comCEL-SCI Reports Fiscal Second Quarter 2026 ResultsMay 18, 2026 | businesswire.comCel-Sci: Fiscal Q2 Earnings SnapshotMay 15, 2026 | chron.comCEL-SCI Announces Closing of Public OfferingMay 13, 2026 | businesswire.comCEL-SCI Corporation Announces Pricing of Public OfferingMay 11, 2026 | businesswire.comCEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi ArabiaMay 11, 2026 | pharmiweb.comPCEL-SCI CorporationMay 5, 2026 | edition.cnn.comCEL-SCI Reports Fiscal First Quarter 2026 ResultsFebruary 18, 2026 | finance.yahoo.comCEL-SCI (CVM) price target decreased by 91.67% to 25.50February 4, 2026 | msn.comWhy did CVM shares rally over 7% today?January 27, 2026 | msn.comCEL-SCI Reports Fiscal 2025 ResultsDecember 29, 2025 | finance.yahoo.comCEL-SCI files to sell 375,000 shares of common stock for holdersNovember 7, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion TargetBy Jeffrey Neal Johnson | July 10, 2026AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in FocusBy Jessica Mitacek | July 3, 2026Qualcomm’s Investor Day Just Changed the Growth Story ForeverBy Sam Quirke | June 29, 2026Why Wall Street Still Sees Massive Upside for AeroVironment StockBy Thomas Hughes | June 30, 2026AST SpaceMobile’s Next Launches Could Decide Whether Its Rally Regains OrbitBy Jessica Mitacek | July 13, 2026BLU, CVM, and OXB Company DescriptionsBELLUS Health TSE:BLUBluenergies Ltd. is engaged in the business of mineral exploration and the acquisition of mineral property assets in Canada. Its objective is to locate and develop economic precious and base metal properties of merit and to conduct its exploration program on the Lemon Lake Property.Cel-Sci NYSEAMERICAN:CVM$1.18 -0.01 (-0.84%) Closing price 07/24/2026 04:10 PM EasternExtended Trading$1.19 +0.01 (+0.93%) As of 07/24/2026 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade? Broadcom May Be the Biggest Winner From Alphabet's Earnings CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
